Q32 Bio Inc. 8-K

What Happened Q32 Bio Inc. (QTTB) filed an 8-K on June 16, 2026 reporting the results of its 2026 Annual Meeting of Stockholders. Shareholders representing 11,833,800 shares (75.71% of the 15,629,463 shares entitled to vote as of the April 15, 2026 record date) participated in the vote. Stockholders elected three Class II directors for three-year terms (ending in 2029), ratified Ernst & Young LLP as the Company’s independent registered public accounting firm for fiscal 2026, and approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers.

Key Details

• Director elections (three-year terms to 2029):
  • Kathleen LaPorte: 7,187,421 votes for; 1,428,633 withheld; 3,217,746 broker non‑votes.
  • Jodie Morrison: 8,591,626 votes for; 24,428 withheld; 3,217,746 broker non‑votes.
  • Arthur Tzianabos, Ph.D.: 8,310,837 votes for; 305,217 withheld; 3,217,746 broker non‑votes.
• Auditor ratification: Ernst & Young LLP ratified with 11,821,046 votes for, 7,909 against, and 4,845 abstentions.
• Advisory executive compensation vote: approved with 8,072,067 votes for, 400,598 against, 143,389 abstentions, and 3,217,746 broker non‑votes.

Why It Matters

• Board continuity: The election of the three Class II directors secures the Company’s board composition through 2029, which affects corporate governance and strategic oversight.
• Audit continuity: Ratifying Ernst & Young LLP maintains the Company’s independent auditor for fiscal 2026, supporting continuity in financial reporting and audit processes.
• Shareholder sentiment on pay: The non‑binding advisory approval shows majority support for executive compensation as disclosed in the proxy, though the result is advisory and not legally binding. Large broker non‑votes on director and pay items indicate a portion of shares were not voted on these non‑routine matters.